Trial Profile
A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 27 Oct 2023
Price :
$35
*
At a glance
- Drugs Anetumab ravtansine (Primary) ; Bevacizumab (Primary) ; Paclitaxel (Primary)
- Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 24 Oct 2023 Planned End Date changed from 21 Oct 2023 to 21 Oct 2024.
- 24 Oct 2023 Planned primary completion date changed from 21 Oct 2023 to 21 Oct 2024.
- 22 Oct 2022 Planned End Date changed from 21 Oct 2022 to 21 Oct 2023.